On March 11, 2020 the WHO declared outbreak COVID-19 as pandemic.This disease was considered as a widespread epidemic caused by the emergence of a new virus or infectious carrier against which the human population has no immunity.The major complication caused by COVID-19, is bilateral interstitial pneumonia, which often requires emergency invasive or noninvasive pulmonary ventilation.On March 8, 2020 BG registered the first cases of COVID-19 in the town of Pleven and Gabrovo.As of March 30,2020 there are confirmed cases of people with COVID-19 in 21 out of 28 BG provinces.In view of the expectation for an increase number of patients in the country and taking into account the analysis of the material and technical assets of the medical establishments,it was concluded that in order diagnostic and treatment options for patients to be strengthened and developed,there is a need for investment in the strands:Apparatus for invasive respiratory ventilation,beds,specialized portable unit,specialized equipment for COVID-19 laboratories;Diagnostics for primary and confirmatory diagnostics for medical establishments for hospital care(MEHC) and scientific(translational)laboratories(TL)/National Center of Infectious and Parasitic Diseases(NCIPD);Supply of Personal Protective Equipment(PPE) for hospitals,Regional Health Inspectorates, centers for transfusion hematology and Centers for Emergency MS.On the one hand, the implementation of these investments will provide for the required level of apparatus in the hospitals,where patients with COVID-19 will be treated, and for the structures responsible for provision of the medical tests and disease diagnosis.On the other hand, the implementation of the investments will ensure the necessary protection to medical and non-medical staff who will have direct contact with the patients.This accomplishment will enable the country to minimize the risk of complications and death,as well as to provide a high level of medical services to citizens.
Overview
Status | In execution (starting date) |
---|---|
Start date | 08 Apr, 2020 |
End date | 08 Sep, 2021 |
Contract date | 08 Apr, 2020 |
Programme
Beneficiary
Financial information
Total cost | 40,439,291.10 |
---|---|
Grant | 40,439,291.10 |
Self finance | 0.00 |
Total paid | 32,351,432.88 |
EU participation percent | 85.0% |
Location